Ningbo David Medical Device Co., Ltd. Class A

Ningbo David Medical Device Co., Ltd. Class A

SSZSE:300314
14.31
CNY
-0.73
(-4.85%)
0.32EPS
40.21P/E
3.70BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.75
0.81
0.78
0.94
1.03
1.04
1.26
1.59
1.66
1.77
2.14
1.84
2.01
2.13
Basic EPS, GAAP
0.22
0.19
0.16
0.22
0.16
0.1
0.22
0.47
0.28
0.34
0.51
0.2
0.3
0.32
Free Cash Flow per Basic Share
0.03
0.11
0.04
0.06
0.07
0.19
0.28
0.39
0.16
0.22
0.33
-0.16
0.12
- -
Dividend per Share
0.1
0.05
0.06
0.04
0.06
0.05
0.09
0.04
0.15
0.1
0.15
0.18
0.09
- -
Book Value per Share
2.18
2.32
2.42
2.6
2.7
2.75
2.88
3.31
3.44
3.68
4.04
4.06
4.28
4.47
Tangible Book Value per Share
2.07
2.21
2.32
2.49
2.59
2.64
2.77
3.21
3.34
3.5
3.88
3.9
4.12
4.31
Basic Weighted Avg Shares
288
282
281
283
294
288
282
290
286
286
289
286
290
288
Sales/Revenue/Turnover
217
227
219
265
304
300
356
460
474
506
618
527
584
613
Operating Margin (%)
28.86
24.01
20.58
23.48
20.42
14.88
15.47
22.17
15.45
19.13
23.16
13.86
13.95
12.78
Depreciation Expense
8
9
9
12
17
21
21
21
25
26
27
27
25
- -
Net Income, GAAP
64
54
45
62
47
29
62
136
80
97
148
57
87
92
Effective Tax Rate (%)
14.91
16.27
16.66
15.78
20.08
27.78
11.1
7.13
8.01
13.01
11.2
9.65
11.76
10.76
Profit Margin (%)
29.49
23.6
20.48
23.46
15.48
9.59
17.41
29.64
16.92
19.24
23.87
10.87
14.91
15.04
Working Capital
474
487
415
417
442
500
544
638
691
746
795
669
683
723
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
9
6
3
2
Total Equity
628
669
698
749
778
793
829
954
991
1,059
1,163
1,168
1,233
1,286
Return on Invested Capital (%)
10.25
8.18
6.42
8.14
6.3
3.88
7.86
15.32
8.18
9.32
13.4
5.27
7.2
7.32
Return on Capital (%)
10.5
7.09
5.58
8.39
6.16
3.27
7.65
15.28
8.25
9.46
13.16
4.9
7.24
7.4
Return on Common Equity (%)
10.5
8.27
6.57
8.6
6.16
3.67
7.65
15.28
8.25
9.5
13.28
4.91
7.25
7.42

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
288
288
288
Market Capitalization
3,643
2,681
3,704

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
902
920
947
Cash, Cash Equivalents & STI
603
596
626
Accounts Receivable, Net
40
40
36
Inventories
212
229
229
Total Current Liabilities
201
230
224
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.93%
5.32%
5.53%
Free Cash Flow
2.54%
-58.5%
-174.68%
Net Income, GAAP
23.28%
4.54%
52.02%
Sales/Revenue/Turnover
11%
5.63%
10.82%
Total Cash Common Dividend
28.98%
52%
-51.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
155
110
137
124
527
2025
121
130
- -
191
584
2026
113
139
169
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.03
0.06
-0.02
0.2
2025
0.08
0.1
- -
0.05
0.3
2026
0.03
0.05
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.12
- -
0.18
2025
- -
- -
- -
- -
0.09
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zai Hong Chen
Full Time Employees
920
Sector
Health technology
Industry
Medical specialties
Address
No.No. 2, Keyuan Road Ningbo ZH China 315731
IPO Date
Apr 23, 2012
Business
Ningbo David Medical Device Co., Ltd. (300314.SZ) develops, manufactures, and sells medical devices primarily focused on neonatal and maternal care equipment. The company offers a comprehensive range of products including infant warmers, infant incubators, radiant warmers, jaundice meters, air and oxygen blenders, phototherapy units, resuscitation units, transport incubators, and monitoring systems such as cardiotocographs and ultrasound Doppler fetal monitors; it also provides consumables and accessories for these devices. Founded in 1997 and headquartered in Ningbo, China, the company operates primarily in the domestic Chinese market with expanding international presence in Asia, Europe, and other regions through distributors and partnerships. The company's core business segments encompass neonatal intensive care solutions, maternal health monitoring, and respiratory support equipment, targeting hospitals, clinics, and healthcare providers specializing in pediatrics and obstetrics. Subsidiaries include Ningbo David Medical Technology Co., Ltd. for R&D and manufacturing enhancements. No significant parent company relationships are reported. In recent developments within the last two years, Ningbo David Medical Device expanded its product portfolio with new launches including advanced transport incubator models and upgraded jaundice management systems to meet evolving regulatory standards in China and export markets. The company secured strategic partnerships with international distributors in Southeast Asia and Europe to broaden geographic reach, alongside participation in key funding for R&D through Shenzhen Stock Exchange listings supporting innovation in smart medical devices. Additionally, it underwent operational enhancements such as facility expansions in Ningbo to increase production capacity by over 20% amid rising demand for neonatal care amid China's aging population and healthcare reforms.